JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 138 filers reported holding JUNO THERAPEUTICS INC in Q3 2015. The put-call ratio across all filers is 2.12 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $90,002,000 | -24.9% | 1,969,053 | -26.3% | 0.01% | -30.0% |
| Q3 2017 | $119,826,000 | +23.9% | 2,671,123 | -17.5% | 0.01% | +11.1% |
| Q2 2017 | $96,742,000 | +44.7% | 3,236,384 | +7.4% | 0.01% | +50.0% |
| Q1 2017 | $66,871,000 | +3.9% | 3,013,630 | -11.8% | 0.01% | 0.0% |
| Q4 2016 | $64,380,000 | -27.0% | 3,415,744 | +16.3% | 0.01% | -33.3% |
| Q3 2016 | $88,156,000 | +38.3% | 2,937,700 | +77.1% | 0.01% | +28.6% |
| Q2 2016 | $63,764,000 | +37.4% | 1,658,792 | +36.1% | 0.01% | +40.0% |
| Q1 2016 | $46,412,000 | +4.7% | 1,218,468 | +20.8% | 0.01% | 0.0% |
| Q4 2015 | $44,344,000 | +26.9% | 1,008,449 | +17.5% | 0.01% | +25.0% |
| Q3 2015 | $34,932,000 | +23.0% | 858,512 | +61.3% | 0.00% | +33.3% |
| Q2 2015 | $28,391,000 | +551.0% | 532,372 | +640.1% | 0.00% | – |
| Q1 2015 | $4,361,000 | – | 71,931 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |